ASCLETIS-B (01672) announced it will present multiple projects via poster sessions at the American Diabetes Association's 2026 Scientific Sessions, scheduled for June 5-8, 2026, in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small molecule amylin receptor agonist with selectivity and high potency for treating obesity, which is modeled after eloralintide. The ASC39 data has been selected for a late-breaking poster presentation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments